J&J. (J&J) has revealed that it has completed enrolment procedures for its efficacy study of a HIV preventative vaccine from its subsidiary, Janssen . The phase IIb trial for the J&J. vaccine now has five female participants in the between 18 and 35 age range from five African countries with high HIV rates. The trial is the first efficacy study conducted in relation to Janssen’s mosaic-based preventive vaccine and is testing whether it can safely and effectively reduce the rate of new HIV infections. The treatment will include Paul Stoffels from a variety of viral gene subtypes behind the HIV virus, with the aim of triggering an immune response. If a safe and effective vaccine can be created, it could help to significantly reduce the rate of new infections, according to J&J.
J&J. (J&J) has revealed that it has completed enrolment procedures for its efficacy study of a HIV preventative vaccine from its subsidiary, Janssen . The phase IIb trial for the J&J. vaccine now has five female participants in the between 18 and 35 age range from five African countries with high HIV rates. The treatment will include Paul Stoffels from a variety of viral gene subtypes behind the HIV virus, with the aim of triggering an immune response. If a safe and effective vaccine can be created, it could help to significantly reduce the rate of new infections, according to J&J.